about us. We are dedicated to realizing the potential of natural killer (NK) cells for the treatment of cancer. Our proprietary technology is designed to harness the power of these important pathogen-fighting immune cells and is uniquely capable of enhancing …

Nkarta's two lead programs are NKX101: Engineered to target NKG2D ligands and NKX019: Engineered to target CD19

2022年4月29日 · 美国时间4月25日，Nkarta Therapeutic（后称：Nkarta）公布了公司两款CAR-NK在研管线NKX101（靶向NKG2D）和NKX019（靶向CD19）治疗血液瘤的最新临床数据。

2020年12月5日 · Nkarta：CAR-NK细胞治疗领域中又一新星 作者：蹊之美股生物医药

2022年12月5日 · Clinical Activity in NXK019 Nineteen patients who received NKX019 were assessed (See table 2). In the two highest dose cohorts (1 B cells x 3 and 1.5 B cells x 3), 8 out of 10 patients with NHL achieved an objective response (80% ORR) and 7 out of 10 achieved a complete response (70% CR). 5 of 6 patients with NHL in the cohort receiving 3 doses of 1 billion cells achieved a response (83% ORR ...

NK cells are the cornerstone of innate immune surveillance. Allogeneic cell source that can be scaled for off-the-shelf production; Proprietary expansion, persistence, cryopreservation and tumor targeting technologies

In this episode of Nkata Podcast: Art & Processes, host Emeka Okereke engages in a compelling conversation with Nigerian painter, designer, and multimedia artist Ibe Ananaba. A lifelong explorer of visual storytelling, Ananaba’s journey... Read More

2025年2月25日 · Nkarta is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies.

Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic natural killer (NK) cell therapies. By combining its cell expansion and cryopreservation platform with ...

Share your videos with friends, family, and the world